• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Martin Celine Christine claimed no ownership of stock in the company (SEC Form 3)

    7/2/26 5:06:31 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Martin Celine Christine

    (Last)(First)(Middle)
    C/O CONMED CORPORATION
    11311 CONCEPT BOULEVARD

    (Street)
    LARGO FLORIDA 33773

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/01/2026
    3. Issuer Name and Ticker or Trading Symbol
    CONMED Corp [ CNMD ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock0D(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Celine Christine Martin became a Director of CONMED on July 1, 2026.
    /s/ Thomas Fistek for Celine Christine Martin by Power of Attorney07/02/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $CNMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    7/9/2026$36.00Market Perform
    BMO Capital Markets
    6/29/2026$40.00Neutral → Underperform
    BofA Securities
    3/17/2026$39.00Overweight → Neutral
    Piper Sandler
    6/12/2025Buy → Hold
    Needham
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    More analyst ratings

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Executive Vice President & CFO Gallagher John E

    4 - CONMED Corp (0000816956) (Issuer)

    7/17/26 3:09:22 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Gallagher John E claimed no ownership of stock in the company (SEC Form 3)

    3 - CONMED Corp (0000816956) (Issuer)

    7/17/26 3:05:51 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Martin Celine Christine

    4 - CONMED Corp (0000816956) (Issuer)

    7/2/26 5:15:25 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting

    Professor Nikhil Vasdev to Present Results of a Recently Published Clinical Trial Featuring AirSeal® technology CONMED Corporation (NYSE:CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdominal insufflators, CONMED’s AirSeal® Insufflation System and Stryker’s PneumoClear Insufflator. TITLE: Utilising i

    7/20/26 7:00:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Cor

    7/2/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

    CONMED Corporation (NYSE:CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer ("CFO"), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. "We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "John brings deep healthcare and medical technology experience, an extensive history of public company leadership, and a proven track record of leading global finance organizations and supporting complex strategic initiatives. His combination of industry experti

    6/17/26 4:35:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/14/24 3:37:54 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/10/24 5:29:04 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/8/24 4:20:48 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    SEC Filings

    View All

    CONMED Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - CONMED Corp (0000816956) (Filer)

    6/17/26 4:49:40 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 11-K filed by CONMED Corporation

    11-K - CONMED Corp (0000816956) (Filer)

    6/16/26 4:30:58 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - CONMED Corp (0000816956) (Filer)

    6/4/26 7:30:38 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on CONMED with a new price target

    BMO Capital Markets initiated coverage of CONMED with a rating of Market Perform and set a new price target of $36.00

    7/9/26 9:27:23 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by BofA Securities with a new price target

    BofA Securities downgraded CONMED from Neutral to Underperform and set a new price target of $40.00

    6/29/26 8:56:54 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded CONMED from Overweight to Neutral and set a new price target of $39.00

    3/17/26 7:55:41 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Financials

    Live finance-specific insights

    View All

    CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Cor

    7/2/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces First Quarter 2026 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from the exit of certain GI products. International revenue increased 4.7% year-over-year as reported and 1.0% in constant currency. International sales growth was impacted by a $0.3 million decrease in sales from the exit of c

    4/29/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic

    4/2/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Leadership Updates

    Live Leadership Updates

    View All

    CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

    CONMED Corporation (NYSE:CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer ("CFO"), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. "We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "John brings deep healthcare and medical technology experience, an extensive history of public company leadership, and a proven track record of leading global finance organizations and supporting complex strategic initiatives. His combination of industry experti

    6/17/26 4:35:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors ("Board"), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of nine directors. "My fellow directors and I are delighted to welcome Celine Martin and Jeff Mirviss to the Board, both highly accomplished leaders with extensive experience developed at two of the largest companies in the healt

    5/20/26 8:30:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

    5/21/25 7:03:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/13/24 4:22:22 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/12/24 12:53:28 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    2/13/24 5:02:29 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care